ENDP Endo International plc

7.65
+0.01  (0%)
Previous Close 7.64
Open 7.61
Price To book 2.11
Market Cap 1708184320
Shares 223,292,068
Volume 4,807,527
Short Ratio 4.55
Av. Daily Volume 6,425,554

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Advisory Committee Meeting March 14, 2017 voted 18 to eight that the benefits of reformulated OPANA ER no longer outweigh its risks.
OPANA ER
Management of pain
Phase 2 trial did not meet endpoint
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Approved October 26, 2015.
BEMA Buprenorphine
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate
CRL issued May 30 2013. Approved March 6 2014.
AVEED (testosterone undecanoate) intramuscular injection
Men diagnosed with hypogonadism
Phase 2b data released November 17, 2016. Met endpoints. Phase 3 planned for 2H 2017.
XIAFLEX
Edematous fibrosclerotic panniculopathy (“cellulite”)

Latest News

  1. See what the IHS Markit Score report has to say about Endo International PLC.
  2. Amneal, Impax combine to tackle generic drug pricing pressure
  3. DEADLINE TODAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm
  4. ENDP DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017
  5. DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm
  6. ENDP FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline: October 17, 2017
  7. DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP
  8. Endo International Plc – Value Analysis (NASDAQ:ENDP) : October 16, 2017
  9. Endo International Plc breached its 50 day moving average in a Bearish Manner : ENDP-US : October 13, 2017
  10. Is Endo International plc (ENDP) Undervalued?
  11. APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm
  12. The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (ENDP)
  13. ONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm
  14. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP
  15. Investor ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) - Lead Plaintiff Deadline: October 17, 2017
  16. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm
  17. ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017
  18. Endo to Announce Third-Quarter 2017 Financial Results

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171075954
  2. S-8 - Securities to be offered to employees in employee benefit plans 171016590
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014085
  4. 8-K - Current report 171013169
  5. 8-K - Current report 171000928
  6. 8-K/A [Amend] - Current report 17999858
  7. 8-K - Current report 17975525
  8. 8-K - Current report 17951437
  9. 8-K - Current report 17946168
  10. 8-K - Current report 17902873